{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Randomized, Open-Label Study of  Atebimetinib in Combination with the Modified  Gemcitabine and nab Paclitaxel Regimen Versus  the Standard Gemcitabine and nab-Paclitaxel  Regimen for the Treatment of Patients with  Metastatic Pancreatic Ductal Adenocarcinoma Cancer","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-randomized-open-label-study-of-atebimetinib-in-combination-with-the-modified-gemcitabine-and-nab-paclitaxel-regimen-versus-the-standard-gemcitabine-and-nab-paclitaxel-regimen-for-the-tr\/#breadcrumbitem"}]}